Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.50 |
| ▸ | RELA | Q04206 | 5/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8355012 | 1.00 | GAA (0.55) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL1661965 | 1.00 | GAA (0.55) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL10054766 | 0.86 | GAA (0.51) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL7801965 | 0.84 | GAA (0.37) | GAANFKB1NFKB2RELA | |
| SCHEMBL7403132 | 0.84 | GAA (0.37) | GAANFKB1NFKB2RELA | |
| SCHEMBL7403136 | 0.84 | GAA (0.37) | GAANFKB1NFKB2RELA | |
| SCHEMBL29217279 | 0.84 | GAA (0.52) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL19021605 | 0.84 | GAA (0.52) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL14159811 | 0.79 | GAA (0.51) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL14308598 | 0.78 | GAA (0.47) | GAANFKB1NFKB2RELABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2306994-B1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2306994-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7842685-B2 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009154775-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-1581480-B1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE-V INHIBITORS | PFIZER LTD (GB) | 2006-08-23 | — | — | EP | disclosed |
| US-7045653-B2 | cyclopentyl substituted glutaramide derivatives; inhibitors of neutral endopeptidase which may be used to treat cardiovascular disorders, especially hypertension | PFIZER, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050075392-A1 | Novel pharmaceuticals | DACK KEVIN NEIL (GB) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075392-A1 | Novel pharmaceuticals | MME, ECE1, ECE2 | GAA 1335/4885NFKB1 4609/4885NFKB2 4451/4885 |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | S1PR1, S1PR5, S1PR2 | GAA 4071/4885NFKB1 2004/4885NFKB2 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.